Recognition of SARS-CoV-2 variants of concern
We have previously produced a number of RBD’s variants, including the
UK, Brazilian and Indian VOC (29, 30) and shown, as others, that
mutations at position E484K strongly reduce recognition by convalescent
sera (30, 31). It is therefore of significant interest that our vaccine
induced immune sera recognized all variant RBDs equally well as the wild
type RBD (Fig 4A and B). Hence, this vaccine candidate may have the
potential to protect against all VoC that occurred up to now equally
well.